Recent senatorial hearings reflect the move to convict UPFs (ultra-processed food) as the culprit responsible for society’s obesity and juvenile metabolic diseases “epidemics” while deflecting focus ...

Liver cancer is the fourth most common cancer in Malaysia and the fourth leading cause of cancer-related deaths, with 1,700 ...

NASH is asymptomatic in a large proportion (48-100%) of patients and it is often discovered incidentally during evaluation for unrelated medical condition. Stigmata of chronic liver disease are ...

Non-alcoholic Fatty Liver Disease ... metabolic dysfunction. Clesacostat is an investigational acetyl-CoA carboxylase (ACC) inhibitor developed by Pfizer for the treatment of non-alcoholic fatty liver ...

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Formerly known as nonalcoholic fatty liver disease (NALFD) MASLD occurs when fat builds up to more than 5 to 10 percent of your ...

Metabolic syndrome is a constellation of conditions that together increase the risk of type 2 diabetes, stroke, and cardiovascular problems, including heart attack. The features of metabolic syndrome ...

No difference in survival was observed compared with non-lean NAFLD (p=0.069). Conclusions Caucasian lean subjects with NAFLD may progress to advanced liver disease, develop metabolic comorbidities ..

TB was the underlying or contributing cause of death of 6% of total TB cases reported in 2022. The incidence of TB per 100,000 in 2023 varied across provinces and territories. Range of TB incidence ...

Fatty acid synthase (FASN), an enzyme that drives de novo lipogenesis, plays a relevant role in metabolic disorders such as obesity, non-alcoholic fatty liver disease (NAFLD) or type 2 diabetes.

A study shows that patients with obesity and fatty liver ... causes of metabolic dysfunction-associated steatohepatitis (MASH), which is the most common form of chronic liver disease in the ...

“We showed, regardless of the stage of disease ... disorder called metabolic dysfunction-associated steatohepatitis, or MASH, formerly known as non-alcoholic fatty liver disease.